Related Experiment Videos
[Interleukin-2 in oncology]
1Laboratoire d'hémato-immunologie, INSERM U333, Institut Gustave-Roussy, Villejuif.
La Revue Du Praticien
|March 11, 1991
Summary
No abstract available in PubMed .
Related Concept Videos
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology.
ESMO open·2023
Same author
Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3(+) )-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates.
Clinical and experimental immunology·2011
Same author
Soluble CD30 and lymphocyte activation gene-3 (CD223), as potential serological markers of T helper-type cytokine response induced by acellular pertussis vaccine.
International journal of immunopathology and pharmacology·2006
Same author
LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathway.
European journal of immunology·2001
Same author
T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts.
European journal of cancer (Oxford, England : 1990)·2001
Same author
KIR down-regulation on NK cells is associated with down-regulation of activating receptors and NK cell inactivation.
European journal of immunology·2001
Same journal
[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].
La Revue du praticien·2026